Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_provenance.
- befree-20150227 importedOn "2015-02-27" NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_provenance.
- NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_assertion wasGeneratedBy ECO_0000203 NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_provenance.
- NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_assertion wasDerivedFrom befree-20150227 NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_provenance.
- NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_assertion SIO_000772 23086750 NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_provenance.
- NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_assertion evidence source_evidence_literature NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_provenance.
- NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_assertion description "[We have assessed the impact of these mutations in a cohort of 494 patients treated within the randomized phase 3 United Kingdom Leukaemia Research Fund Chronic Lymphocytic Leukemia 4 (UK LRF CCL4) trial that compared chlorambucil and fludarabine with and without cyclophosphamide in previously untreated patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP826274.RAjHX2SDOAnfVrykU_dn0tr0KZGUnKQg_Qez0_gESEZbM130_provenance.